indication

For the treatment of congestive heart failure.

pharmacology

Enoximone is a phosphodiesterase inhibitor (type III) that increases the force of contraction of the heart and dilates blood vessels. In June 2005, Myogen announced that they were discontinuing development of enoximone due to negative results. The drug is approved for use in the UK.

mechanism of action

Further research is required to determine accurately the mechanism of action of drugs with phosphodiesterase inhibitory activity, however, inhibition of PDE3 inhibits degredation of cGMP. This allows for increased NO release and vascular relaxation.

biotransformation

Hepatic oxidation

absorption

Bioavailabvility is 50% following oral administration.

half life

4-10 hours